- Home
- IQV vs TAK Comparison
IQV vs TAK Comparison
Compare IQV & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQV | TAK |
|---|---|---|
| Founded | 1982 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 43.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | IQV | TAK |
|---|---|---|
| Price | $221.33 | $14.94 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $237.59 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.30 | 0.14 |
| Revenue | $15,904,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $5.35 | $0.59 |
| P/E Ratio | ★ $30.47 | $106.44 |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $134.65 | $12.80 |
| 52 Week High | $234.30 | $15.69 |
Technical Indicators
Market Signals| Indicator | IQV | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 67.77 |
| Support Level | $220.12 | $14.43 |
| Resistance Level | $225.80 | $14.66 |
| Average True Range (ATR) | 5.19 | 0.16 |
| MACD | -1.06 | 0.05 |
| Stochastic Oscillator | 35.74 | 90.00 |
Price Performance
Historical ComparisonAbout IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.